At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 81–90 of 607 results.
-
Surgery is the primary treatment for skin cancer. Patients' perception of the scar following surgery for facial skin cancer may significantly influence their satisfaction with their care. The purpose of this study is to assess patients' satisfaction with the appearance of their face and scar after skin cancer surgery at Memorial Sloan Kettering Cancer Center (MSK), as well as their quality of life after the surgery.
-
The goal of this study is to find the best dose of lenalidomide that can be given together with the usual combination chemotherapy in adults with HTLV-associated T-cell leukemia-lymphoma. The usual chemotherapy consists of the drugs etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) and is known as EPOCH. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma.
-
In this study, researchers are comparing the effectiveness bevacizumab plus osimertinib versus osimertinib alone as initial treatment for patients with stage IIIB-IV non-small cell lung cancer that contains a mutation in a gene called EGFR.
-
The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early-onset colorectal cancer (diagnosed before age 50). Researchers will observe and track changes in hormone levels and in sexual and reproductive health in the study participants. This information will help them learn more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).
-
Cetuximab binds to a protein called EGFR, which is found on some types of tumor cells. This drug may help keep tumor cells from growing. Pembrolizumab helps the body's immune system attack the tumor and may interfere with tumor growth and spread.
-
Researchers are assessing tepotinib with or without ramucirumab in people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has metastasized (spread) or recurred (came back) after treatment. Their cancers also have a genetic change called the MET exon 14 skipping mutation.
-
Researchers want to find the best dose of eganelisib when used alone and with cytarabine to treat leukemia. The people in this study have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) that has come back or keeps growing after treatment.          
-
A standard approach for early-stage rectal cancer is treatment with chemotherapy and radiation therapy followed by surgery. In this study, researchers are comparing two approaches to prevent the need for rectal resection (removal of all or nearly all of the rectum) in people with early rectal cancer: chemotherapy or chemotherapy and radiation with observation or limited surgery (removing only the area with the tumor, not the entire rectum).
-
Researchers are assessing the use of cobimetinib to treat Langerhans cell histiocytosis (LCH) and other histiocytic disorders. Histiocytic disorders are diseases caused by the abnormal function or buildup of immune cells called histiocytes. Cobimetinib works by blocking the activity of a protein called MEK. This protein leads to the abnormal growth and development of histiocytosis cells.
-
Cancer and its treatment may affect sexual and reproductive health. The purpose of this study is to evaluate sexual and reproductive health over several years among women age 50 and younger newly diagnosed with breast cancer or lymphoma.